| [1] |
李剑红，王丽敏，李镒冲，等．2010年我国成年血脂异常流行特点[J].中华预防医学杂志, 2012, 46(5): 414-418．
|
| [2] |
李剑虹，王丽敏，米生权，等．2010年我国成年人血脂异常知晓率和治疗率及控制率调查[J].中华预防医学杂志, 2012, 46(8): 687-691．
|
| [4] |
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment PanelⅢ)[J].JAMA, 2001, 285(19): 2486-2497.
|
| [5] |
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panelⅢguidelines[J]. Circulation, 2004, 110(2):227-239.
|
| [6] |
European Association for Cardiovascular Prevention & Rehabilitation1, Reiner Z, Catapano AL, et a1. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology(ESC) and the European Atherosclerosis Society(EAS)[J]. Eur Heart J, 2011, 32(14): 1769-1818.
|
| [7] |
Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report[J]. J Clin Lipidol, 2014, 8(1): 29-60.
|
| [8] |
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2889-2934.
|
| [9] |
Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary[J]. J Clin Lipidol, 2014, 8(5): 473-488.
|
| [10] |
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias[J]. Eur Heart J, 2016, 37(39): 2999-3058.
|
| [11] |
Tonelli M, Wanner C, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline[J]. Ann Intern Med, 2014, 160(3): 182.
|
| [12] |
Marx N. Commentary on 'Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis' by Preiss et al[J]. Diab Vasc Dis Res, 2012, 9(1): 78.
|
| [13] |
Bettermann K, Arnold AM, Williamson J, et a1. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study[J]. J Stroke Cerebrovasc Dis, 2012, 21(6): 436-444.
|